Role of Pirfenidone in the Management of Pulmonary Fibrosis

Therapeutics and Clinical Risk Management
doi 10.2147/tcrm.s81141
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Idiopathic Pulmonary Fibrosis and Pirfenidone

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2010English

Efficacy of Pirfenidone in Patients With Advanced-Stage Idiopathic Pulmonary Fibrosis

Internal Medicine
Internal MedicineMedicine
2013English

Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis: Nationwide Danish Results

European Clinical Respiratory Journal
2016English

Erratum To: Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events

Advances in Therapy
MedicinePharmacology
2014English

Pirfenidone Inhibits Fibrocyte Accumulation in the Lungs in Bleomycin-Induced Murine Pulmonary Fibrosis

Respiratory Research
PulmonaryRespiratory Medicine
2014English

Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis

Annals of Thoracic Surgery
Respiratory MedicinePulmonaryCardiovascular MedicineSurgeryCardiology
2016English

Pirfenidone Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice by Regulating Nrf2/Bach1 Equilibrium

BMC Pulmonary Medicine
PulmonaryRespiratory Medicine
2017English

Advances in the Management of Idiopathic Pulmonary Fibrosis

F1000 Medicine Reports
2010English

The Role of miRNAs in Idiopathic Pulmonary Fibrosis

2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy